What is the recommended dose for ipratropium bromide (IPR) and albuterol sulfate (ALB) inhalation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Dosing for Ipratropium Bromide and Albuterol Sulfate Inhalation

For acute asthma or COPD exacerbations in adults, administer 3 mL of the combination nebulizer solution (containing 0.5 mg ipratropium bromide and 2.5 mg albuterol sulfate) every 20 minutes for 3 doses, then as needed; alternatively, use 8 puffs via MDI every 20 minutes for up to 3 hours. 1

Nebulizer Dosing

Adults

  • Acute exacerbations: 3 mL of combination solution (0.5 mg ipratropium + 2.5 mg albuterol) every 20 minutes for 3 doses, then as needed 1, 2
  • Maintenance therapy: The combination can be administered three to four times daily with doses 6-8 hours apart for stable COPD 3
  • Dilute aerosols to a minimum of 3 mL at gas flow of 6-8 L/min for optimal delivery 1

Pediatric Patients (≤12 years)

  • Acute exacerbations: 1.5 mL of combination solution every 20 minutes for 3 doses, then as needed 1, 2
  • For very young children (including infants), use half doses of approximately 100-125 mcg ipratropium 2

Metered-Dose Inhaler (MDI) Dosing

Adults

  • Acute exacerbations: 8 puffs (each puff contains 18 mcg ipratropium + 90 mcg albuterol) every 20 minutes as needed for up to 3 hours 1, 4
  • Maintenance therapy: 2 puffs four times daily for stable disease 4, 5

Pediatric Patients

  • Acute exacerbations: 4-8 puffs every 20 minutes as needed for up to 3 hours 1, 2
  • Must use with valved holding chamber (spacer) and face mask for children <4 years 1

Individual Component Dosing

Ipratropium Bromide Alone

Nebulizer:

  • Adults: 0.5 mg every 20 minutes for 3 doses, then as needed 1, 2
  • Children: 0.25-0.5 mg every 20 minutes for 3 doses, then as needed 1
  • FDA-approved maintenance dosing: 500 mcg three to four times daily, with doses 6-8 hours apart 6

MDI:

  • Adults: 8 puffs (18 mcg/puff) every 20 minutes as needed for up to 3 hours 1, 4
  • Children: 4-8 puffs every 20 minutes as needed for up to 3 hours 1

Albuterol Sulfate Alone

Nebulizer:

  • Adults: 2.5-5 mg every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours as needed 1
  • Children: 0.15 mg/kg (minimum 2.5 mg) every 20 minutes for 3 doses, then 0.15-0.3 mg/kg every 1-4 hours as needed 1

MDI:

  • Adults and children: 4-8 puffs every 20 minutes for 3 doses, then every 1-4 hours as needed 1

Critical Clinical Considerations

When to Add Ipratropium

  • Do not use ipratropium as first-line monotherapy for acute asthma exacerbations 1, 4
  • Add ipratropium to short-acting beta-agonist (SABA) therapy for severe exacerbations, particularly when FEV1 or PEF <40% predicted 1, 2
  • Consider adding ipratropium when patients fail to improve after 15-30 minutes of initial beta-agonist therapy 2

Duration of Combination Therapy

  • The combination may be used for up to 3 hours in initial management of severe exacerbations 1, 2
  • Important caveat: The addition of ipratropium to albuterol has not been shown to provide further benefit once the patient is hospitalized 1, 2

Administration Technique

  • MDI with valved holding chamber is as effective as nebulized therapy when administered with appropriate technique and coaching 1, 5
  • For nebulizer use, ensure adequate flow rate of 6-8 L/min with oxygen-driven nebulizer 1
  • Ipratropium can be mixed in the same nebulizer with albuterol or metaproterenol if used within one hour 6

Evidence for Combination Therapy

  • High-dose combination therapy (ipratropium + albuterol) produces 48% greater improvement in FEV1 compared to albuterol alone in acute exacerbations 7
  • The combination reduces hospital admission risk by 49% (relative risk 0.51) compared to albuterol alone 7
  • Patients with FEV1 ≤30% predicted and symptom duration ≥24 hours benefit most from combination therapy 7
  • For stable COPD, combination therapy provides better bronchodilation than either agent alone without increasing adverse effects 3, 8

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Bromuro de Ipratropio Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Ipratropium Inhaler Dosing for Adults

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

MDI Atrovent Dosing for Acute COPD Exacerbation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.